Peter Joseph Pappas preeclampsia research grant recipients' study titles and reports.
Two articles were published this quarter that both provide updated statistics about trends in preeclampsia and hypertensive disorders of pregnancy in the United States.
In this study, HMOX1 gene variants were different depending on ancestry, and these genetic changes could be contributing to the racial disparity in hypertensive disorders of pregnancy.
These results highlight two new biomarkers with a possibility of being able to predict timing of onset and subtypes of preeclampsia well before preeclampsia is diagnosed.
This group of studies supports the role of our gut microbiome on preeclampsia risk. Future studies may explore changing the gut microbiome (for example by antibiotics, probiotics, or prebiotics) to help prevent preeclampsia.
This study suggests that eating ultra-processed foods can increase risk for preeclampsia.
The Preeclampsia Foundation and the Preeclampsia Foundation Canada have announced that John Snelgrove, MD, MSc, and Samantha Wilson, PhD, are their 2022 Vision Grant research award recipients respectively.
Investigators meeting the research funding program’s criteria are invited to submit Letters of Intent for 2022 proposals by August 22, 2022.
Researchers study a new "rule-out" test for preeclampsia which looks at eight different biomarkers.
Research study investigates whether expectant management or early delivery is more beneficial to mom and baby in women with preeclampsia between 34-36 weeks.
Research study finds a clear link between experiencing a hypertensive disorder of pregnancy and risk for cardiovascular disease 30 years later.
Treatment for Mild Chronic Hypertension during Pregnancy (Results from the CHAPS Trial) Treating mild chronic hypertension with medications during pregnancy is beneficial and safe for mother and baby, according to the results of a study published...